Genesis Pharmaceuticals Enterprises, Inc. continued its steady flow of announcements by reporting a new cooperative agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS). IMCAS, which performs basic and applied research in microbiology, will work with Genesis to improve the commercialization of pharmaceutical discoveries. Genesis will be responsible for funding the daily operations of the collaboration, which will take place at IMCAS. When drugs have completed the first stage of experiments, Genesis will conduct further testing in its own facility to determine the feasibility of commercial-scale production. More details...

Stock Symbol: (OTCBB: GTEC)